Rigel Pharmaceuticals Incis A Biotechnology Company Based In South San Franciscocaliforniait Focuses On Discoveringdevelopingand Commercializing Small Molecule Drugs Aimed At Treating Hematologic Disorderscancersand Immune Related Diseasesfounded In The Late 1990S And Going Public In November 2000Rigel Has Built A Strong Pipeline Through Clinical Research And Strategic Partnerships With Companies Like Bergenbiodaiichi Sankyoand Eli Lilly The Company S Portfolio Includes Fda Approved Therapies Such As Fostamatinib Disodium Hexahydrate For Chronic Immune Thrombocytopeniaolutasidenib Capsules For Acute Myeloid Leukemia With Idh1 Mutationsand Pralsetinib Capsules For Non Small Cell Lung Cancer With Ret Gene Alterationsrigel Also Has Investigational Therapies In Its Pipeline Targeting Various Autoimmune And Oncologic Conditionsthe Company Emphasizes Precision Medicinefocusing On Small Molecule Inhibitors That Enhance Patient Compliance Through Oral Administration
